Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | DGKA | P23743 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20152005 | 0.89 | DGKA (0.43) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL14990807 | 0.87 | ADRA2A (0.48) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL18751710 | 0.87 | MEN1 (0.40) | BLMMEN1KMT2A | |
| SCHEMBL18751714 | 0.87 | MEN1 (0.40) | BLMMEN1KMT2A | |
| SCHEMBL26382110 | 0.87 | MEN1 (0.40) | BLMMEN1KMT2A | |
| SCHEMBL18751713 | 0.87 | MEN1 (0.40) | BLMMEN1KMT2A | |
| SCHEMBL18751718 | 0.87 | MEN1 (0.40) | BLMMEN1KMT2A | |
| SCHEMBL18751712 | 0.87 | MEN1 (0.40) | BLMMEN1KMT2A | |
| SCHEMBL18751715 | 0.87 | MEN1 (0.40) | BLMMEN1KMT2A | |
| SCHEMBL25818821 | 0.87 | MEN1 (0.40) | BLMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226219-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226219-A1 | PEG LIPIDOID COMPOUNDS | LIPG, ABCB4, HDLBP | ADRA2A 4124/4885ADRA1A 4013/4885MAPT 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.